[144] STERIS plc SEC Filing

Rhea-AI Filing Summary

STERIS plc reports a Form 144 notice for the proposed sale of 3,204 ordinary shares via Charles Schwab & Co., Inc. on 08/20/2025 with an aggregate market value of $798,560.00 and 98,490,606 shares outstanding. The shares were acquired on 08/20/2025 through an employee stock option exercise with a broker-facilitated cashless exercise and payment. The filer certifies no undisclosed material adverse information about the issuer.

Positive

• Transaction clearly documented: acquisition date, nature (employee stock option exercise), broker, share count and aggregate value are provided
• Cashless exercise used: indicates a standard broker-facilitated liquidity mechanism for option holders
• No prior sales reported in past three months: the filing states "Nothing to Report" for recent sales

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider option exercise and planned sale; size is immaterial versus outstanding shares.

The filing documents a same-day employee stock option exercise followed by a broker-assisted cashless sale of 3,204 ordinary shares valued at $798,560.00. Against the reported 98,490,606 shares outstanding, this represents a de minimis percentage of the company, indicating limited direct market impact. No prior sales in the past three months were reported. This is a standard compensation liquidity event rather than a change in corporate strategy.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags present in the notice.

The Form 144 provides required details: acquisition date, nature of acquisition (employee stock option exercise), broker, number of shares, and aggregate value. The signer affirms lack of undisclosed material adverse information. There is no indication of clustered insider selling or atypical timing disclosed here. Documentation appears compliant with disclosure norms for insider sales under Rule 144.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	3204	798560.00	98490606	08/20/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary	08/20/2025	Employee Stock Option Exercise	STERIS plc			3204	08/20/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did STERIS (STE) report on Form 144?

The filer reported a proposed sale of 3,204 ordinary shares to be executed via Charles Schwab on 08/20/2025 with an aggregate market value of $798,560.00.

How were the shares acquired according to the filing?

The shares were acquired on 08/20/2025 through an employee stock option exercise and the payment was handled by a broker cashless exercise.

How large is the sale relative to STERIS's outstanding shares?

The filing lists 98,490,606 shares outstanding; the 3,204 shares represent a de minimis portion of that total.

Were any securities sold by this person in the past three months?

No. The filing explicitly reports "Nothing to Report" for securities sold during the past three months.

Does the filer assert any undisclosed material information?

By signing, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.